Krane Funds Advisors LLC Purchases New Position in Teladoc Health, Inc. (NYSE:TDOC)

Krane Funds Advisors LLC bought a new position in Teladoc Health, Inc. (NYSE:TDOC) in the fourth quarter, HoldingsChannel reports. The fund bought 12,962 shares of the health services provider’s stock, valued at approximately $118,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Versant Capital Management Inc increased its stake in shares of Teladoc Health by 313.8% in the fourth quarter. Versant Capital Management Inc now owns 3,219 shares of the health services provider’s stock valued at $29,000 after buying an additional 2,441 shares during the period. Whipplewood Advisors LLC bought a new position in Teladoc Health in the fourth quarter worth approximately $29,000. Lindbrook Capital LLC grew its holdings in shares of Teladoc Health by 78.9% during the fourth quarter. Lindbrook Capital LLC now owns 3,654 shares of the health services provider’s stock valued at $33,000 after buying an additional 1,612 shares during the last quarter. Pilgrim Partners Asia Pte Ltd bought a new position in Teladoc Health in the 4th quarter valued at about $60,000. Finally, Generali Investments Management Co LLC purchased a new stake in shares of Teladoc Health in the fourth quarter worth approximately $64,000. Institutional investors and hedge funds own 76.82% of the company’s stock.

Teladoc Health Stock Performance

Shares of TDOC opened at $7.26 on Monday. The company has a current ratio of 1.73, a quick ratio of 1.69 and a debt-to-equity ratio of 0.66. The stock has a 50-day moving average price of $10.14 and a 200-day moving average price of $9.78. The company has a market cap of $1.26 billion, a PE ratio of -1.26 and a beta of 1.73. Teladoc Health, Inc. has a 12-month low of $6.76 and a 12-month high of $15.21.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings results on Wednesday, February 26th. The health services provider reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.07). The company had revenue of $640.49 million during the quarter, compared to analysts’ expectations of $639.44 million. Teladoc Health had a negative return on equity of 10.06% and a negative net margin of 37.91%. As a group, equities analysts forecast that Teladoc Health, Inc. will post -1.16 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Adam C. Vandervoort sold 11,011 shares of the firm’s stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $8.42, for a total transaction of $92,712.62. Following the transaction, the insider now directly owns 64,308 shares of the company’s stock, valued at approximately $541,473.36. This trade represents a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.95% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Royal Bank of Canada raised their price objective on Teladoc Health from $11.00 to $12.00 and gave the company an “outperform” rating in a research note on Friday, January 24th. Needham & Company LLC reissued a “hold” rating on shares of Teladoc Health in a research report on Thursday, February 27th. Bank of America raised their price objective on shares of Teladoc Health from $11.50 to $13.50 and gave the stock a “neutral” rating in a report on Wednesday, February 12th. The Goldman Sachs Group dropped their price objective on Teladoc Health from $16.00 to $13.00 and set a “buy” rating on the stock in a research note on Monday, March 3rd. Finally, Oppenheimer reduced their price objective on Teladoc Health from $14.00 to $12.00 and set an “outperform” rating for the company in a report on Friday, January 24th. Eleven research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $11.26.

Teladoc Health Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.